About Cellerix
Cellerix is a Healthcare company based in Madrid (Spain) founded in 2004, and was acquired by TiGenix in February 2011. Stem Cell Therapy for the treatment of gastroenterology, dermatology, and immune-based diseases. Cellerix has raised $78.5 million across 2 funding rounds from investors including Roche, Life Sciences Partners and TiGenix. Its focus areas include Diversified Pharmaceuticals, Drugs, Life Sciences and Cell Therapy.
Company details
Founded in 2004 in Madrid, Spain, the company operates in the biotechnology sector, focusing on adult stem cell-based medicines. Treatments are developed for conditions in gastroenterology, dermatology, and immunology. Key products include Cx401, applied to complex perianal fistulas, and Cx501, used for Epidermolysis Bullosa. Production and development activities are centered on regenerative cell therapies.
- Headquarters Madrid, Spain
- Stage Acquired
- SectorsHealthcare
- Website cellerix.com
- Social LinkedIn
- Acquired by TiGenix (Feb 2011)
Funding Insights of Cellerix
Cellerix has successfully raised a total of $78.5M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $40.5 million completed in November 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78.5M
- Total Rounds 2
- Last Round Series C — $40.5M
- First Round $38M
(Sep 2007)
- Investors Count 5
All 2 funding rounds of Cellerix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2009 | $40.5M | Series C | – | – | |
| Sep 2007 | $38M | Series B | – | – |
6 investors in total: 6 institutional.
Investors in Cellerix
Cellerix has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Life Sciences Partners and TiGenix.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Ysios Capital is recognized as a leading life sciences investor. | ysioscapital.com | Barcelona, Spain | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Early-stage funding is provided to innovative founders by Ventech. | ventechvc.com | Paris, France | ||
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland | |
Allogeneic stem cell-based therapies targeting autoimmune, inflammatory and heart diseases. | 2000 | tigenix.com | Leuven, Belgium |
Investor details for Cellerix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cellerix
4 dated milestones of Cellerix across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Cellerix is founded.
- Funding First funding round of $38.0M.
- Funding Latest funding round, Series C, of $40.5M.
- Exit Acquired by TiGenix.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cellerix
Cellerix was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Cellerix is headquartered in Madrid, Spain. It is registered at Madrid, Madrid, Spain.
Cellerix is a funded company, having raised a total of $78.5M across 2 funding rounds to date. The company's 1st funding round was a Series B of $38M, raised on Sep 2007.
Founded in 2004 in Madrid, Spain, the company operates in the biotechnology sector, focusing on adult stem cell-based medicines. Treatments are developed for conditions in gastroenterology, dermatology, and immunology. Key products include Cx401, applied to complex perianal fistulas, and Cx501, used for Epidermolysis Bullosa. Production and development activities are centered on regenerative cell therapies.
Cellerix has 6 investors. Key investors include Roche, Life Sciences Partners, TiGenix, Ysios Capital, and Novartis Venture Fund.
Yes. Cellerix was acquired by TiGenix in February 2011.